An electric motor includes a rotor and a stator. The stator includes a first stator segment including a first annular back portion, a first tooth extending radially inward from the first annular back portion, a first flange extending away from the first tooth, a first insulation portion at least partially covering the first annular back portion, the first tooth, and the first flange, and a first coil wound around the first tooth. The stator also includes a second stator segment separate from the first stator segment and axially coupled to the first stator segment, the second stator segment including a second annular back portion, a second tooth extending radially inward from the second annular back portion, a second flange extending away from the second tooth and toward the first flange, a second insulation portion at least partially covering the second annular back portion, the second tooth, and the second flange.

The cold pressure welding apparatus includes a first holding part capable of sandwiching a first flat conductor, a second holding part disposed opposite to the first holding part and capable of sandwiching a second flat conductor, and a drive part for moving the first holding part and the second holding part. The drive part can move the first holding part and the second holding part between a first direction separated position and a close position along a first direction. The drive part can move the first holding part and the second holding part between a second direction separated position and a sandwiching position along a second direction.

Compositions comprising donor cells, acceptor cells, and methods involving the same are described herein. In some embodiments, the donor cell is deficient in at least one endogenous function, for instance cytotoxic activity. In some embodiments, the donor cell comprises a T cell receptor (TCR) and a cargo, and the acceptor cell comprises an MHC. In some embodiments, the TCR facilitates transfer of the cargo to the acceptor cell. In some embodiments, the donor cell comprises a chimeric antigen receptor (CAR) and a cargo, and the acceptor cell comprises an antigen bound by the CAR. In some embodiments, the CAR facilitates transfer of the cargo to the acceptor cell.

The present application relates to a chimeric antigen receptor, comprising a first antigen binding domain and a second antigen binding domain. The first antigen binding domain targets a G protein-coupled receptor class C group 5 member D (GPRC5D) protein, and the second antigen binding domain targets the GPRC5D protein. The present application further provides a cell comprising the chimeric antigen receptor and use thereof.

The present invention provides an immunoconjugate having the formula:

T-c-E.sub.n-c-Fc.sub.n or T-c-Fc.sub.n-c-E.sub.n;

wherein, T is a single chain variable portion fragment of a monoclonal antibody (scFv) directed to a target protein, polypeptide, or fragment thereof, which is highly expressed on cancer cells; E is two or more foreign immunogenic CD8.sup.+ T cell antigenic epitopes; c is a peptide or polypeptide fragment thereof, capable of being cleaved by a specific protease; and Fc is two or more Fc portions of an IgG antibody. Nucleic acid sequences encoding the same and vectors containing said nucleic acid sequences are also provided. Methods of making the immunoconjugate, along with methods of making target cells susceptible to CTL mediated cell killing, and methods for treatment of cancers are also provided.

Embodiments of the present disclosure concern administration of a cell population to an individual for regeneration of a tissue. The cell population may comprise fibroblasts and/or immune cells, either of which may be modified or unmodified. The tissue for regeneration may be a thymus.

Embodiments of the present disclosure concern administration of a cell population to an individual for regeneration of a tissue. The cell population may comprise fibroblasts and/or immune cells, either of which may be modified or unmodified. The tissue for regeneration may be a thymus.

The present invention provides an immunoconjugate having the formula: T-c-E.sub.n-c-Fc.sub.n or T-c-Fc.sub.n-c-E.sub.n; wherein, T is a single chain variable portion fragment of a monoclonal antibody (scFv) directed to a target protein, polypeptide, or fragment thereof, which is highly expressed on cancer cells; E is two or more foreign immunogenic CD8.sup.+ T cell antigenic epitopes; c is a peptide or polypeptide fragment thereof, capable of being cleaved by a specific protease; and Fc is two or more Fc portions of an IgG antibody. Nucleic acid sequences encoding the same and vectors containing said nucleic acid sequences are also provided. Methods of making the immunoconjugate, along with methods of making target cells susceptible to CTL mediated cell killing, and methods for treatment of cancers are also provided.

A method of treating a T cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (HSP 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (IDDM) or rheumatoid arthritis. The administering of the immunogenic composition results in a shift of the immune response to a Th2 response, thereby treating the disease.

Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.